KAMADA LTD. Inactive Instrument
Kamada Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0010941198
Pharmaceuticals
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 59Cr 16Cr 5.87TCr 1.32TCr | Sales 2025 * | 66Cr 18Cr 6.64TCr 1.49TCr | Capitalization | 117.43Cr 32Cr 12TCr 2.64TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 5.5Cr 1.48Cr 550Cr 123.6Cr | Net income 2025 * | 6.6Cr 1.78Cr 660Cr 148.32Cr | EV / Sales 2024 * | 2 x |
| Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 1.77 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 09/13/09 |
David Tsur
FOU | Founder | 73 | 13/90/13 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 31/17/31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 24/19/24 |
Leon Recanati
BRD | Director/Board Member | 76 | 01/05/01 |
David Tsur
FOU | Founder | 73 | 13/90/13 |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
14/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.10% | 8.91TCr | |
| +2.76% | 4.09TCr | |
| -12.92% | 3.22TCr | |
| +54.69% | 2.51TCr | |
| -16.51% | 1.54TCr | |
| -8.27% | 1.19TCr | |
| -42.60% | 1.19TCr | |
| -12.82% | 1.16TCr | |
| +7.34% | 903.23Cr |
